Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 8/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263122 | 0.89 | KMT2A (0.40) | SMN1; SMN2KMT2AMEN1POLBADRB2 | |
| SCHEMBL14693113 | 0.88 | KMT2A (0.51) | SMN1; SMN2KMT2AMEN1POLBADRB2 | |
| SCHEMBL1084994 | 0.83 | MEN1 (0.62) | GAAKMT2AMEN1POLBKDM4E | |
| SCHEMBL3211335 | 0.82 | DRD2 (0.48) | MAPTALDH1A1PIK3CDTSHR | |
| SCHEMBL1084309 | 0.79 | KMT2A (0.49) | GAASMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL13439444 | 0.79 | GAA (0.46) | GAASMN1; SMN2KMT2AMEN1SMARCA2 | |
| SCHEMBL14340933 | 0.78 | KMT2A (0.47) | GAASMN1; SMN2KMT2AMEN1POLB | |
| SCHEMBL12991321 | 0.78 | MAPT (0.46) | GAASMN1; SMN2KMT2AMEN1SMARCA2 | |
| SCHEMBL3532899 | 0.78 | SMN1; SMN2 (0.47) | GAASMN1; SMN2KMT2AMEN1SMARCA2 | |
| SCHEMBL12781798 | 0.78 | SMN1; SMN2 (0.53) | GAASMN1; SMN2KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372843-B2 | Quinolines useful as modulators of ION channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683066-B2 | Isoquinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| WO-2006127329-A1 | QUINOLINE DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137331-A1 | Quinolines Useful as Modulators of ION Channels | KCNQ1, KCNQ2, KCNQ5 | GAA 1480/4885SMN1; SMN2 1298/4885KMT2A 1962/4885 |
| US-20070099873-A1 | Quinolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNQ5 | GAA 1480/4885SMN1; SMN2 1298/4885KMT2A 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.